Enrolling by invitationPHASE2, PHASE3NCT05374590
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
Studying Adult-onset myasthenia gravis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- argenx
- Intervention
- Efgartigimod IV or Efgartigimod PH20 SC(biological)
- Enrollment
- 12 enrolled
- Eligibility
- 2-18 years · All sexes
- Timeline
- 2022 – 2029
Study locations (16)
- Ann and Robert H Lurie Children's Hospital of Chicago - Main Hospital, Chicago, Illinois, United States
- Atrium Health Neurology Specialty Care, Charlotte, North Carolina, United States
- University of Virginia (UVA) Health - Developmental Pediatrics Clinic, Charlottesville, Virginia, United States
- Universitair Ziekenhuis Antwerpen, Edegem, Belgium
- UZ Gent, Ghent, Belgium
- Childrens Hospital of Eastern Ontario, Ottawa, Canada
- AP-HM- Hôpital de La Timone, Marseille, France
- Universitätsklinikum Essen, Essen, Germany
- Hadassah Medical Center- Ein Kerem, Jerusalem, Israel
- Leids Universitair Medisch Centrum, Leiden, Netherlands
- Uniwersyteckie Centrum Kliniczne w Gdansku, Gdansk, Poland
- Wielospecjalistyczna Poradnia Lekarska Synapsis, Katowice, Poland
- Centralny Szpital Kliniczny - Uniwersyteckie Centrum Kliniczne WUM, Warsaw, Poland
- Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain
- Great Ormand Street Hospital for Children NHS Foundation Trust - Great Ormond Street Hospital - Pediatric Neurology, London, United Kingdom
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05374590 on ClinicalTrials.govOther trials for Adult-onset myasthenia gravis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06987539A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)Amgen
- RECRUITINGPHASE2NCT07501702A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia GravisVertex Pharmaceuticals Incorporated
- RECRUITINGPHASE1NCT07526493Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.Tongji Hospital
- RECRUITINGNANCT07413835Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)The Affiliated Hospital of Xuzhou Medical University
- RECRUITINGPHASE1, PHASE2NCT07089121Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune DisordersCartesian Therapeutics
- RECRUITINGPHASE1NCT07304154A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic DiseasesKite, A Gilead Company
- RECRUITINGPHASE4NCT07221838A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With RavulizumabAlexion Pharmaceuticals, Inc.
- RECRUITINGPHASE1, PHASE2NCT07250750A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia GravisImmunAbs Inc.